Last updated:
On December 8, 2011, the New York Times published an article noting the results of a recent U.S. Food and Drug Administration (F.D.A.) hearing on the popular birth control pills, Yaz and Yasmin, both manufactured by Bayer. The F.D.A.’s advisory committee discussed studies that provide conflicting evidence on the incidence of blood clotting events in women taking these drospirenone-based oral contraceptives. Recent studies have indicated that drospirenone, a synthetic version of the hormone progestin found in Yaz and Yasmin, may raise a woman’s risk of developing blood clots, which can lead to serious health problems. However, studies funded by Bayer have not found this increased level of incidence for blood clotting in women taking Yaz or Yasmin.
In light of these conflicting studies, the advisory committee recommended changing the product labeling for these oral contraceptives. The committee agreed that the labeling should include a warning about the conflicting evidence that exists regarding possible blood clotting in women who use these pills. The new product labeling will inform women of the possible risk for blood clots when taking Yaz or Yasmin. Although the committee found a change in product labeling necessary, it still felt that the benefits provided by these oral contraceptives outweigh the risks.
Recent lawsuits brought against Bayer, the company that manufactures both Yasmin and Yaz, claim that multiple women were harmed by taking these oral contraceptives. These lawsuits connect these birth control pills to approximately 100 deaths, according to court documents. Plaintiffs in these lawsuits also accuse Bayer of knowingly concealing unfavorable blood clot data results from the F.D.A. in 2004.
See the full New York Times article at:
http://www.nytimes.com/2011/12/09/health/policy/stronger-label-urged-for-yaz-and-yasmin-contraceptives.html
Hurt in a dangerous drugs & devices situation?
Talk directly with John David Hart — board-certified Texas trial lawyer. Free, confidential, no fee unless we win.
Get a Free Case Review Call 817-870-2102More on Dangerous Drugs & Devices
How we handle Dangerous Drugs & Devices →Good News for EpiPen® Auto-Injector Users and Families!
Mylan today issued a statement announcing that it is taking immediate action to increase access to EpiPen® Auto-Injectors by expanding already existing…
Continue reading »Outrageous
In an August 22, 2016, New York Times article, Tara Parker-Pope and Rachel Rabkin Peachman reported on the steep increase in the…
Continue reading »Is It Possible to Keep Up with Product Recalls?
How do we stay safe and keep our families safe when products we use are recalled for safety reasons? Safety recalls are…
Continue reading »